中危非肌层浸润性膀胱癌的辅助膀胱内治疗
这项多中心回顾性研究纳入2206例中危非肌层浸润性膀胱癌患者,评估辅助膀胱内治疗对肿瘤学结局的影响。辅助治疗与更好的无复发生存期相关(HR 0.79,95%CI 0.70-0.89,P<0.001),但与无进展生存期无关(P=0.09)。在无危险因素亚组中,辅助治疗未带来明确的复发率降低。
要点
- 辅助膀胱内治疗与中危NMIBC患者更好的RFS相关(HR 0.79,95%CI 0.70-0.89,P<0.001)。
- 辅助治疗与PFS无关(P=0.09)。
- 无危险因素亚组中辅助治疗未与RFS显著相关(HR 0.71,95%CI 0.50-1.02,P=0.06)。
核心结论
- 在中危NMIBC患者中,辅助膀胱内治疗在RFS方面带来获益。
- 在无危险因素的患者中,辅助膀胱内治疗未导致复发率明确降低。
研究设计与样本
- 多中心回顾性研究,纳入接受经尿道膀胱肿瘤电切术的Ta期患者,排除低危和高危NMIBC,共2206例中危NMIBC患者。
主要发现
- 1427例患者接受辅助治疗,包括卡介苗(n=168)或化疗药物如丝裂霉素C或表柔比星(n=1259),方案不同,最长至1年。
- 中位随访73.3个月(四分位距38.4-106.9)。
- 接受辅助治疗与未接受辅助治疗患者的1年和5年RFS分别为72.6% vs 69.5%和50.8% vs 41.3%。
- 辅助治疗与更好的RFS相关(HR 0.79,95%CI 0.70-0.89,P<0.001),但与PFS无关(P=0.09)。
- 在年龄≤70岁、原发性、单发Ta Grade 2 <3 cm肿瘤亚组(n=328)中,辅助治疗与RFS无关(HR 0.71,95%CI 0.50-1.02,P=0.06)。
临床怎么用
- 作者认为中危NMIBC患者可从辅助膀胱内治疗中获得RFS获益。
- 作者指出无危险因素的患者中辅助膀胱内治疗未导致复发率明确降低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of adjuvant therapy on oncological outcomes in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC), as due to the poorly-defined and overlapping diagnostic criteria optimal decision-making remains challenging in these patients. PATIENTS AND METHODS: In this multicentre study, patients treated with transurethral resection of bladder tumour for Ta disease were retrospectively analysed. All patients with low- or high-risk NMIBC were excluded from the analysis. Associations between adjuvant therapy administration with recurrence-free survival (RFS) and progression-free survival (PFS) rates were assessed in Cox regression models. RESULTS: A total of 2206 patients with intermediate-risk NMIBC were included in the analysis. Among them, 1427 patients underwent adjuvant therapy, such as bacille Calmette-Guérin (n = 168), or chemotherapeutic agents, such as mitomycin C or epirubicin (n = 1259), in different regimens up to 1 year. The median (interquartile range) follow-up was 73.3 (38.4-106.9) months. The RFS at 1 and 5 years in patients treated with adjuvant therapy and those without were 72.6% vs 69.5% and 50.8% vs 41.3%, respectively. Adjuvant therapy was associated with better RFS (hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.70-0.89, P < 0.001), but not with PFS (P = 0.09). In the subgroup of patients aged ≤70 years with primary, single Ta Grade 2 <3 cm tumours (n = 328), adjuvant therapy was not associated with RFS (HR 0.71, 95% CI 0.50-1.02, P = 0.06). While in the subgroup of patients with at least one risk factor including patient age >70 years, tumour multiplicity, recurrent tumour and tumour size ≥3 cm (n = 1878), adjuvant intravesical therapy was associated with improved RFS (HR 0.78, 95% CI 0.68-0.88, P < 0.001). CONCLUSION: In our study, patients with intermediate-risk NMIBC benefit from adjuvant intravesical therapy in terms of RFS. However, in patients without risk factors, adjuvant intravesical therapy did not result in a clear reduction in the recurrence rate.
引用
- Laukhtina E, Gontero P, Babjuk M, et al. Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer. BJU Int. 2024. PMID: 38627025. doi:10.1111/bju.16371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。